{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:24:35Z","timestamp":1770071075245,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,11,9]]},"DOI":"10.1038\/s41416-022-01951-y","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T19:02:49Z","timestamp":1665601369000},"page":"1827-1836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review"],"prefix":"10.1038","volume":"127","author":[{"given":"Youssra","family":"Al Hajji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-9563","authenticated-orcid":false,"given":"Thomas","family":"Starkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennard Y. W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-4860","authenticated-orcid":false,"given":"Michael","family":"Tilby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"1951_CR1","unstructured":"World Health Organisation. Coronavirus disease (COVID-19) pandemic. World Health Organisation. 2020. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019"},{"key":"1951_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907\u201318.","journal-title":"Lancet"},{"key":"1951_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430\u20136.","journal-title":"Nature"},{"key":"1951_CR4","doi-asserted-by":"crossref","unstructured":"Elkrief A, Desilets A, Papneja N, Cvetkovic L, Groleau C, Lakehal YA, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study. Eur J Cancer. 2020;139:181\u20137.","DOI":"10.1016\/j.ejca.2020.08.017"},{"key":"1951_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2020.09.035","volume":"141","author":"A Li\u00e8vre","year":"2020","unstructured":"Li\u00e8vre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer. 2020;141:62\u201381.","journal-title":"Eur J Cancer"},{"key":"1951_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2020.09.027","volume":"141","author":"K de Joode","year":"2020","unstructured":"de Joode K, Dumoulin DW, Tol J, Westgeest HM, Beerepoot LV, van den Berkmortel FWPJ, et al. Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171\u201384.","journal-title":"Eur J Cancer"},{"key":"1951_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","volume":"139","author":"KS Saini","year":"2020","unstructured":"Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43\u201350.","journal-title":"Eur J Cancer"},{"key":"1951_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2020.09.028","volume":"141","author":"E Yeked\u00fcz","year":"2020","unstructured":"Yeked\u00fcz E, Utkan G, \u00dcr\u00fcn Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer. 2020;141:92\u2013104.","journal-title":"Eur J Cancer"},{"key":"1951_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914\u201322.","journal-title":"Lancet Oncol"},{"key":"1951_CR10","doi-asserted-by":"publisher","first-page":"e220130.","DOI":"10.1001\/jamanetworkopen.2022.0130","volume":"5","author":"C V\u00e1rnai","year":"2022","unstructured":"V\u00e1rnai C, Palles C, Arnold R, Curley HM, Purshouse K, Cheng VWT, et al. Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19. JAMA Netw Open. 2022;5:e220130.","journal-title":"JAMA Netw Open"},{"key":"1951_CR11","doi-asserted-by":"crossref","unstructured":"Booth S, Curley HM, Varnai C, Arnold R, Lee LY, Campton NA, et al. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. Br J Haematol. 2022;196:892\u2013901.","DOI":"10.1111\/bjh.17937"},{"key":"1951_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577.","journal-title":"N Engl J Med"},{"key":"1951_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99\u2013111.","journal-title":"Lancet"},{"key":"1951_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl J Med. 2021;384:403\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","journal-title":"N. Engl J Med"},{"key":"1951_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.annonc.2021.10.014","volume":"33","author":"C Corti","year":"2022","unstructured":"Corti C, Antonarelli G, Scott\u00e9 F, Spano JP, Barri\u00e8re J, Michot JM, et al. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review. Ann Oncol. 2022;33:158\u201368.","journal-title":"Ann Oncol"},{"key":"1951_CR16","doi-asserted-by":"crossref","unstructured":"Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, Mesa-Chavez F, Barrientos-Guti\u00e9rrez T, Tagliamento M, et al. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;160:243\u201360.","DOI":"10.1016\/j.ejca.2021.10.014"},{"key":"1951_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"15","author":"A Sakuraba","year":"2022","unstructured":"Sakuraba A, Luna A, Micic D. Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. J Hematol Oncol. 2022;15:15 https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7.","journal-title":"J Hematol Oncol"},{"key":"1951_CR18","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"APS Munro","year":"2021","unstructured":"Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258\u201376.","journal-title":"Lancet"},{"key":"1951_CR19","unstructured":"Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination, 30 December 2020. GOV.UK. 2022. https:\/\/www.gov.uk\/government\/publications\/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020\/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020"},{"key":"1951_CR20","unstructured":"CDC. COVID-19 vaccines for moderately or severely immunocompromised people. Centers for Disease Control and Prevention. 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html"},{"key":"1951_CR21","doi-asserted-by":"publisher","first-page":"e068632.","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"ARYB Lee","year":"2022","unstructured":"Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632.","journal-title":"BMJ"},{"key":"1951_CR22","doi-asserted-by":"publisher","first-page":"n71.","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1951_CR23","doi-asserted-by":"crossref","unstructured":"Yang LM, Costales C, Ramanathan M, Bulterys PL, Murugesan K, Schroers-Martin J, et al. Cell-mediated and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients [Internet]. bioRxiv:2022.01.04.22268750 [Preprint]. 2022 [cited 2022 Mar 2]. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2022.01.04.22268750v1","DOI":"10.1101\/2022.01.04.22268750"},{"key":"1951_CR24","unstructured":"National Institutes of Health. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 2014. https:\/\/www.nhlbi.nih.gov\/health-pro\/guidelines\/in-develop\/cardiovascular-risk-reduction\/tools\/cohort."},{"key":"1951_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ccell.2021.12.013","volume":"40","author":"A Fendler","year":"2022","unstructured":"Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Schmitt AM, et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2022;40:114\u20136.","journal-title":"Cancer Cell"},{"key":"1951_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2021.11.006","volume":"40","author":"LC Shapiro","year":"2022","unstructured":"Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022;40:3\u20135.","journal-title":"Cancer Cell"},{"key":"1951_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/bjh.17982","volume":"196","author":"P Reimann","year":"2022","unstructured":"Reimann P, Ulmer H, Mutschlechner B, Benda M, Severgnini L, Volgger A, et al. Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response. Br J Haematol. 2022;196:577\u201384. https:\/\/doi.org\/10.1111\/bjh.17982.","journal-title":"Br J Haematol"},{"key":"1951_CR28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ajh.26284","volume":"96","author":"K Herzog Tzarfati","year":"2021","unstructured":"Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021;96:1195\u2013203.","journal-title":"Am J Hematol"},{"key":"1951_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1182\/bloodadvances.2021006215","volume":"6","author":"C Bagacean","year":"2022","unstructured":"Bagacean C, Letestu R, Al-Nawakil C, Brichler S, L\u00e9vy V, Sritharan N, et al. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:207\u201311.","journal-title":"Blood Adv"},{"key":"1951_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031\u20133.","journal-title":"Cancer Cell"},{"key":"1951_CR31","doi-asserted-by":"publisher","first-page":"1055.","DOI":"10.3390\/vaccines9101055","volume":"9","author":"J Marlet","year":"2021","unstructured":"Marlet J, Gatault P, Maakaroun Z, Longuet H, Stefic K, Handala L, et al. Antibody responses after a third dose of COVID-19 vaccine in kidney transplant recipients and patients treated for chronic lymphocytic leukemia. Vaccines. 2021;9:1055.","journal-title":"Vaccines"},{"key":"1951_CR32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood.2021014085","volume":"139","author":"Y Herishanu","year":"2022","unstructured":"Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139:678\u201385.","journal-title":"Blood"},{"key":"1951_CR33","doi-asserted-by":"crossref","unstructured":"Fenioux C, Teixeira L, Fourati S, Melica G, Lelievre JD, Gallien S, et al. SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents. JAMA Oncol. 2022; https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-abstract\/2788011","DOI":"10.1001\/jamaoncol.2021.7777"},{"key":"1951_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaoncol.2021.6764","volume":"8","author":"Y Rottenberg","year":"2022","unstructured":"Rottenberg Y, Grinshpun A, Ben-Dov IZ, Oiknine Djian E, Wolf DG, Kadouri L. Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol. 2022;8:300\u20131.","journal-title":"JAMA Oncol"},{"key":"1951_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2021.12.014","volume":"40","author":"C Zeng","year":"2022","unstructured":"Zeng C, Evans JP, Chakravarthy K, Qu P, Reisinger S, Song NS, et al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. 2022;40:117\u20139.","journal-title":"Cancer Cell"},{"key":"1951_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jtho.2021.10.015","volume":"17","author":"V Gounant","year":"2022","unstructured":"Gounant V, Ferr\u00e9 VM, Soussi G, Charpentier C, Flament H, Fidouh N, et al. Efficacy of severe acute respiratory syndrome Coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol. 2022;17:239\u201351.","journal-title":"J Thorac Oncol."},{"key":"1951_CR37","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","volume":"27","author":"RT Shroff","year":"2021","unstructured":"Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27:2002\u201311.","journal-title":"Nat Med."},{"key":"1951_CR38","doi-asserted-by":"crossref","unstructured":"Di Noia V, Pimpinelli F, Renna D, Maccallini MT, Gariazzo L, Riva F, et al. Potentiation of humoral response to BNT162b2 vaccine after the third dose in patients with solid cancer. Ann Oncol. 2022;33:563\u20135.","DOI":"10.1016\/j.annonc.2022.02.006"},{"key":"1951_CR39","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","volume":"5","author":"A Vijenthira","year":"2021","unstructured":"Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5:2624\u201343.","journal-title":"Blood Adv"},{"key":"1951_CR40","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol."},{"key":"1951_CR41","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165\u201373.","journal-title":"Blood."},{"key":"1951_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccell.2021.12.002","volume":"40","author":"V Naranbhai","year":"2022","unstructured":"Naranbhai V, St Denis KJ, Lam EC, Ofoman O, Garcia-Beltran WF, Mairena CB, et al. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. Cancer Cell. 2022;40:103\u2013108.e2.","journal-title":"Cancer Cell."},{"key":"1951_CR43","first-page":"221","volume":"23","author":"K Xing","year":"2021","unstructured":"Xing K, Tu X-Y, Liu M, Liang Z-W, Chen J-N, Li J-J, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23:221\u20138.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"1951_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417\u201322.","journal-title":"Nature"},{"key":"1951_CR45","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022;386:340\u201350.","journal-title":"N Engl J Med"},{"key":"1951_CR46","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205\u201311.","journal-title":"Nat Med"},{"key":"1951_CR47","doi-asserted-by":"publisher","unstructured":"Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022; https:\/\/doi.org\/10.1056\/NEJMoa2116414","DOI":"10.1056\/NEJMoa2116414"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01951-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01951-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01951-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:05:00Z","timestamp":1667952300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01951-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,11,9]]}},"alternative-id":["1951"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01951-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}